link to webcast
Category: Webcast
TG4001+Avelumab vs Avelumab Single-Agent Phase II Update
link to webcast
2024 Half-Year Results
link to webcast
New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
link to webcast
TG4050, First positive clinical data from Phase I clinical trials
link to webcast
First efficacy results of TG4001+avelumab in HPV16-positive cancers
https://channel.royalcast.com/webcast/transgene/20191003_1/
Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
Webcast